Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fuji
Boehringer Ingelheim
Cerilliant
Deloitte
Healthtrust
Federal Trade Commission
US Army
Fish and Richardson
Baxter
Harvard Business School

Generated: December 12, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,919,483

« Back to Dashboard

Which drugs does patent 7,919,483 protect, and when does it expire?


Patent 7,919,483 protects XIMINO and SOLODYN and is included in two NDAs. There have been four Paragraph IV challenges on Solodyn.

This patent has thirteen patent family members in ten countries.

Summary for Patent: 7,919,483

Title:Method for the treatment of acne
Abstract: A method for treatment of acne with tetracyclines is provided. A lower sustained dose and no loading dose is employed, with an optional once-a-day dosing regimen.
Inventor(s): Wortzman; Mitchell (Scottsdale, AZ), Plott; R. Todd (Briscoe, TX), Bhatia; Kuljit (Nesconset, NY), Patel; Bhiku (Chandler, AZ)
Assignee: Medicis Pharmaceutical Corporation (Scottsdale, AZ)
Application Number:11/166,817
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Patented / Exclusive Use
Sun Pharm Inds LtdXIMINOminocycline hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL201922-001Jul 11, 2012RXNoNo► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
Sun Pharm Inds LtdXIMINOminocycline hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL201922-003Jul 11, 2012RXNoNo► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
Sun Pharm Inds LtdXIMINOminocycline hydrochlorideCAPSULE, EXTENDED RELEASE;ORAL201922-005Jul 11, 2012RXNoNo► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
MedicisSOLODYNminocycline hydrochlorideTABLET, EXTENDED RELEASE;ORAL050808-001May 8, 2006DISCNYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
MedicisSOLODYNminocycline hydrochlorideTABLET, EXTENDED RELEASE;ORAL050808-008Aug 27, 2010RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
MedicisSOLODYNminocycline hydrochlorideTABLET, EXTENDED RELEASE;ORAL050808-004Jul 23, 2009RXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
MedicisSOLODYNminocycline hydrochlorideTABLET, EXTENDED RELEASE;ORAL050808-007Aug 27, 2010ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
MedicisSOLODYNminocycline hydrochlorideTABLET, EXTENDED RELEASE;ORAL050808-002May 8, 2006DISCNYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
MedicisSOLODYNminocycline hydrochlorideTABLET, EXTENDED RELEASE;ORAL050808-006Aug 27, 2010ABRXYesNo► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
MedicisSOLODYNminocycline hydrochlorideTABLET, EXTENDED RELEASE;ORAL050808-005Jul 23, 2009RXYesYes► Subscribe► Subscribe► SubscribeTREATMENT OF ACNE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,919,483

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,192,615Method for the treatment of acne and certain dosage forms thereof► Subscribe
7,541,347Minocycline oral dosage forms for the treatment of acne► Subscribe
8,722,650Extended-release minocycline dosage forms► Subscribe
8,252,776Minocycline oral dosage forms for the treatment of acne► Subscribe
8,268,804Minocycline oral dosage forms for the treatment of acne► Subscribe
7,790,705Minocycline oral dosage forms for the treatment of acne► Subscribe
7,544,373Minocycline oral dosage forms for the treatment of acne► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,919,483

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Canada2613273► Subscribe
China101208097► Subscribe
European Patent Office1898925► Subscribe
Israel188331► Subscribe
Japan2013213047► Subscribe
Japan5744976► Subscribe
Japan2008543936► Subscribe
New Zealand564093► Subscribe
World Intellectual Property Organization (WIPO)2007001961► Subscribe
Norway20080444► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Cantor Fitzgerald
Citi
US Army
Baxter
Cipla
McKinsey
Deloitte
Argus Health
Merck
Farmers Insurance

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot